PP
MRNA icon

Paloma Partners’s Moderna MRNA Stock Holding History

Paloma Partners’s Portfolio MRNA Stock Details MRNA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-5,800
Closed -$689K – 1489
2024
Q2 		$689K Buy
5,800
+5,757
+13,388% +$729K 0.02% 626
2024
Q1 		$4.58K Sell
43
-15,157
-100% -$1.53M ﹤0.01% 734
2023
Q4 		$1.51M Sell
15,200
-32,200
-68% -$2.71M 0.06% 328
2023
Q3 		$4.9M Buy
47,400
+15,700
+50% +$1.75M 0.17% 108
2023
Q2 		$3.85M Buy
31,700
+10,300
+48% +$1.37M 0.14% 150
2023
Q1 		$3.29M Buy
+21,400
New +$3.53M 0.12% 148
2022
Q4 		– Sell
-27,300
Closed -$3.23M – 1077
2022
Q3 		$3.23M Sell
27,300
-28,900
-51% -$4.39M 0.15% 117
2022
Q2 		$8.03M Buy
56,200
+52,700
+1,506% +$7.53M 0.28% 42
2022
Q1 		$603K Buy
+3,500
New +$589K 0.02% 648
2021
Q3 		– Sell
-3,500
Closed -$822K – 1606
2021
Q2 		$822K Sell
3,500
-1,400
-29% -$250K 0.01% 740
2021
Q1 		$642K Buy
+4,900
New +$710K 0.01% 953

Other funds holding MRNA

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
TP
Theleme Partners London, United Kingdom $1.5B AUM 19.72% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
FP
Flagship Pioneering Cambridge, Massachusetts $1.16B AUM 67.93% 1-Year Est. Return

Paloma Partners's MRNA Position: Q4 2024 in Review

Paloma Partners sold out of Moderna (MRNA) in Q4 2024, closing a stake of 4,768 shares — an estimated $319K sold.

Paloma Partners first reported a position in MRNA in Q4 2019 and held it in 12 quarters. The position peaked at $3.86M in Q2 2020. 745 funds tracked by Wall St. Rank hold MRNA as of Q4 2024.

  • Paloma Partners reported no remaining Moderna position as of Q4 2024 after selling out during the quarter.
  • Paloma Partners sold 4,768 Moderna shares in Q4 2024, an estimated $319K.
  • Paloma Partners first reported a position in Moderna in Q4 2019 and held it in 12 quarters.
  • Paloma Partners's Moderna position peaked at $3.86M in Q2 2020.
  • 745 funds tracked by Wall St. Rank held Moderna as of Q4 2024.

Based on Paloma Partners's 13F filing for Q4 2024, filed 14 Feb 2025.